Rubidium-82 radionuclide has the advantage to be available on demand from a strontium-82/rubidium-82 generator associated with an infuser and directly connected to a vein of a patient installed on the bed of a PET system.

This device has already obtained the approval for a clinical use in the US. The ease of use and accessibility of the rubidium generators enabled to make the cardiac perfusion analysis accessible to a large number of US nuclear medicine departments unlike nitrogen-13 which needs an on-site cyclotron to be produced.

A new radiopharmaceutical agent (Flurpiridaz) using fluor-18 radionuclide for its production in low energy cyclotron is under final development in the US.